Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M8VE
|
||||
Former ID |
DCL000843
|
||||
Drug Name |
Iloperidone
|
||||
Synonyms |
Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Vanda Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C24H27FN2O4
|
||||
InChI |
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
|
||||
InChIKey |
XMXHEBAFVSFQEX-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 133454-47-4
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
8194581, 12014542, 14905142, 17396835, 43127698, 47359860, 47359861, 47731199, 48404440, 50064358, 51401239, 57318156, 85209859, 92712438, 93301492, 99246148, 99437181, 103176655, 103856472, 103942259, 104350273, 109693466, 117566372, 118050578, 124757285, 124899318, 125164089, 125340171, 126625565, 126656709, 126666080, 129711844, 131297754, 134339308, 135029478, 135587716, 135650377, 135692163, 135697544, 136367918, 137249342, 142584651, 144116064, 144207159, 152344064, 160645064, 162011651, 162037626, 162172136, 163123672
|
||||
SuperDrug ATC ID |
N05AX14
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [530677], [536463] | |
D(2) dopamine receptor | Target Info | Antagonist | [530677], [536463] | ||
PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
SIDS Susceptibility Pathways | |||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
References | |||||
Ref 530677 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | ||||
Ref 543255 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 87). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.